Receptores cannabinoides y vías de modulación del dolor

José Castro-Barragán, María Daniels-García, Alfonso Martínez-Visbal

Resumen


Introducción: los endocannabinoides son mensajeros que contienen ácido araquidóni­co y que se almacenan en vesículas. Los más importantes son N-araquidoniletanolami­na (anandamida) y 2-araquidonilglicerol (2-AG).

Objetivo: reconocer la importancia de los receptores cannabinoides y su papel en las vías de modulación del dolor.

Metodología: se realizó una búsqueda en PubMed, MEDLINE, Scielo, OvidSP, EBSCO­host y en las plataformas de las Revistas Lancet y New England Journal of Medicine, Anesthesiology, entre otras. Las búsquedas se limitaron a los idiomas inglés y español, así como documentos publicados entre 1990 y 2015.

Resultados: se obtuvieron 100 artículos, de los cuales se utilizaron 45 (45%) docu­mentos a conveniencia incluyendo artículos de revisión y artículos originales.

Conclusión: existe evidencia acerca de la presencia de receptores cannabinoides en los sitios de modulación del dolor, principalmente en la sustancia gris periacueductal (SGPA), creando dianas potenciales en el manejo del dolor crónico. Rev.cienc.biomed. 2016;7(1):93-103.

PALABRAS CLAVE

Endocannabinoides; Tetrahidrocannabinol; Modulación antigénica.

SUMMARY

Introduction: the endocannabinoids are messengers that contain arachidonic acid. They are stored in vesicles. The most important are N-arachidonylethanolamine (anan­damide) and 2-arachidonoylglycerol (2-AG).

Objective: to recognize the importance of cannabinoid receptors and their role in pain modulation pathways.

Methods: a research was carried out in PubMed, MEDLINE, Scielo, OvidSP, EBSCOhost, and on the platforms of the Lancet Magazine and New England Journal of Medicine, An­esthesiology, among others. Searches were limited to English and Spanish languages, as well as documents published between 1990 and 2015.

Results: one hundred articles were obtained, of which 45 (45%) documents were cho­sen by convenience including review articles and original papers.

Conclusion: there is evidence about the presence of cannabinoid receptors in pain mod­ulation sites, mainly in the periaqueductal gray (PAGM) substance, creating potential targets in the management of chronic pain. Rev.cienc.biomed. 2016;7(1):93-103.

KEYWORDS

Endocannabinoids; Tetrahydrocannabinol; Antigenic modulation.


Texto completo:

Sin título

Referencias


Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol

Rev 2003; 83:1017–66.

Matsuda LA, Lolait, SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor

and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-4.

Muccioli GG. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug

Discov Today. 2010;15(11-12):474-83.

Howlett AC, Johnson MR, Melvin LS, Milne GM. Nonclassical cannabinoid analgetics inhibit

adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol.

;33(3):297–302.

Munro S, Thomas K.L, Abu-Shaar M. Molecular characterization of a peripheral receptor for

cannabinoids. Nature. 1993;365(6441):61-65.

Díaz I. Mecanismo de transducción de señal de los cannabinoides. Sociedad Española de investigación

sobre cannabinoides (SEIC) 2002.Pp 44-45.

Alvarez J, Palmer J. The role of endocannabinoids in pain modulation and the therapeutic

potential of inhibiting their enzymatic degradation. Current pharmaceutical biotechnology.

;12:1644-59.

Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M,

Mackie K, Martin BR, Mechoulam R, Pertwee RG. International union of pharmacology. XXVII.

Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161–202.

Hohmann, A. G, Herkenham M. Neurosci. Lett. 1998;252:13–16.

Rodríguez U, Carrillo E. Cannabinoides: neurobiología y usos médicos. Elementos.

;12(60):3.

Farmacología de los receptores para cannabinoides; Sociedad Española de Investigación sobre

Cannabinoides (SEIC) Departamento de Bioquímica y Biología Molecular Facultad de Medicina

Universidad Complutense de Madrid 28040 Madrid.

Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the

global burden of disease. Lancet 2012;379:55–70.

Fine P, Rosenfeld M. The Endocannabinoid System, Cannabinoids, and Pain. Rambam Maimonides

Medical Journal. 2013;4:4: e0022.

1Ware M, Desroches J. Cannabis medicinal y dolor. Pain: Clinical Updates. 2014;22: 1 -10.

Volkow N, Baler R. Adverse Health Effects of Marijuana Use. N Engl J Med 2014;370:2219-27.

Actualización sobre el potencial terapéutico de los cannabinoides; Sociedad Española de Investigación

sobre Cannabinoides (SEIC) Departamento de Bioquímica y Biología Molecular Facultad

de Medicina Universidad Complutense de Madrid 28040 Madrid.

Pertwee R. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:

Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol.

;153(2):199-215.

Casadiego A, Lastra S. Cannabis sintético: aspectos toxicológicos, usos clínicos y droga de

diseño. Rev. Fac. Med. 2015;63(3): 501-10.

González S, Sagredo O, Gómez M, Ramos JA. Química y metabolismo de los cannabinoides.

En: Sociedad Española de Investigación Sobre Cannabinoides. Guía básica sobre los cannabinoides.

Madrid: Universidad Complutense de Madrid; 2009. p. 13-22.

Pertwee R. The diverse CB1 and CB2 receptor pharmacology of threeplant cannabinoids:

Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol.

;153(2):199–215.

Fine P, Rosenfeld M. The Endocannabinoid System, Cannabinoids, and Pain. Rambam Maimonides

Med J. 2013;4(4): e0022.

Guzmán M. Galve-Roperh I. Endocannabinoides: un nuevo sistema de comunicación en el cerebro.

Farmacia.2010;11:173-79.

Netzahualcoyotzi, C. Muñoz, N. Martínez, I. Florán, B. Limón, D. La marihuana y el sistema

endocanabinoide: de sus efectos recreativos a la terapéutica. Rev Biomed. 2009;20:128-153.

Whitlow, C. Freedland, C. Porrino, L. Functional consequences of the repeated administration

of Delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend. 2003;71:169-77.

Murillo, E. Drucker, R. Endocanabinoides y su modulación en el sueño. Arch Neurocien, México.

:11(3): 185-93.

Svíženská I, Dubový P, Šulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution,

ligands and functional involvement in nervous system structures — A short review.

Pharmacol Biochem Behav. 2008;90(4):501-11.

Abood ME, Martin BR. Molecular neurobiology of the cannabinoid receptor. International Review

of Neurobiology. 1996;39:197-221.

Society for Neuroscience. Cannabinoids and animal physiology. 1998.

Palazzo E, Luongo L, Novelli V. The role of cannabinoid receptors in the descending modulation

of pain. Pharmaceuticals (Basel). 2010;3(8):2661–73.

Bequet, F., Uzabiaga, F., Desbazeille, M., Ludwiczak, P., Maftouh, M., Picard, C., Scatton, B. &

Le Fur, G. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by

microdialysis coupled with LC/MS) in the rat hypothalamus.Eur. J. Neurosci. 2007;26:3458–64.

18. Croci T, Manara L, Aureggi G, Guagnini F, Rinaldi-Carmona M, Maffrand JP, et al. In vitro

functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol

;125:1393–5.

Hasanein P, Parviz M, Keshavarz M, Javanmardi K. CB1 receptor activation in the basolateral

amygdala produces antinociception in animal models of acute and tonic nociception. Clin Exp

Pharmacol Physiol. 2007;34(5-6):439-49.

Flores. A., Maldonado R., Berrendero F. Cannabinoid-hypocretin cross-talk in the central nervous

system: what we know so far. Journal Neuroscience. 2013;7:256.

Neubert MJ, Kincaid W, Heinricher MM. Nociceptive facilitating neurons in the rostral ventromedial

medulla. Pain. 2004;110:158–165.

Starowicz K., Malek N., Przewlocka B. Cannabinoid receptors and pain. Focus Article.

;2:15-20.

Shu-Jung Hu S. Cheng Ho Y., Chu Chiou L. No more pain upon Gq-protein-coupled receptor

activation: role of endocannabinoids. European Journal of Neuroscience.2014;39: 467–84.

Russo E., Hohmann A. Role of cannabinoids in pain management. GW Pharmaceuticals. Ther

Clin Risk Manag. 2008;4(1):245–259.

Mangieri RA, Piomelli D. Enhancement of endocannabinoid signaling and the pharmacotherapy

of depression. Pharmacol Res. 2007;56(5):360-6.

Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of two endocannabinoid- hydrolyzing

enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and

amygdala. Eur J Neurosci. 2004;20(2):441–58.

Neubert MJ, Kincaid W, Heinricher MM. Nociceptive facilitating neurons in the rostral ventromedial

medulla. Pain. 2004;110:158–65.

Durnett J. Cannabinoids Modulate Pain by Multiple Mechanisms of Action. The Journal of Pain.

;1(1): 2-14.

Walker M, Huang S, Strangman N. Pain modulation by release of the endogenous cannabinoid

anandamide. Rev. Psychology.1999;96(21): 14-25.

Rodríguez U, Carrillo E. Cannabinoides: neurobiología y usos médicos. Elementos.2005;60(12):3

De Novellis V, Mariani L, Palazzo E, VitaD, Marabese I, Scafuro M, Rossi F, Maione S. Periaqueductal

grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate

changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin

in the rat. Neuroscience 2005;134: 269-281.

Rea K, Roche M, Finn D. Supraspinal modulation of pain by cannabinoids: the role of GABA and

glutamate. British Journal of Pharmacology .2007;152:633–648.


Enlaces refback

  • No hay ningún enlace refback.


Revista Ciencias Biomedicas
ISSN 2215-7840 / ISSN-e 2389-7252

Universidad de Cartagena
Facultad de Medicina Zaragocilla cra 50C # 24-120

6698177-6698178

correo-e:revistacienciasbiomedicas@unicartagena.edu.co